Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O. Björkholm M, et al. Among authors: nilsson l. J Clin Oncol. 2011 Jun 10;29(17):2410-5. doi: 10.1200/JCO.2011.34.7542. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537037 Free PMC article.
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM, Travaglino E, Samuelsson J, Hast R, Nilsson L, Cazzola M, Wibom R, Hellström-Lindberg E. Tehranchi R, et al. Among authors: nilsson l. Blood. 2005 Jul 1;106(1):247-53. doi: 10.1182/blood-2004-12-4649. Epub 2005 Mar 8. Blood. 2005. PMID: 15755901 Free article.
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L, Brune M, LeBlanc K, Kutti J, Birgegård G; Swedish Group for Myeloproliferative Disorders. Merup M, et al. Among authors: nilsson l. Br J Haematol. 2006 Nov;135(3):367-73. doi: 10.1111/j.1365-2141.2006.06302.x. Epub 2006 Sep 14. Br J Haematol. 2006. PMID: 16972981 Free article.
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
Nilsson L, Edén P, Olsson E, Månsson R, Astrand-Grundström I, Strömbeck B, Theilgaard-Mönch K, Anderson K, Hast R, Hellström-Lindberg E, Samuelsson J, Bergh G, Nerlov C, Johansson B, Sigvardsson M, Borg A, Jacobsen SE. Nilsson L, et al. Blood. 2007 Oct 15;110(8):3005-14. doi: 10.1182/blood-2007-03-079368. Epub 2007 Jul 6. Blood. 2007. PMID: 17616640 Free article.
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, Oberg G, Jacobsen SE, Hokland P, Porwit A, Hellström-Lindberg E. Grövdal M, et al. Among authors: nilsson l. Clin Cancer Res. 2007 Dec 1;13(23):7107-12. doi: 10.1158/1078-0432.CCR-07-1193. Clin Cancer Res. 2007. PMID: 18056190 Clinical Trial.
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Grövdal M, et al. Among authors: nilsson l. Br J Haematol. 2010 Aug;150(3):293-302. doi: 10.1111/j.1365-2141.2010.08235.x. Epub 2010 May 20. Br J Haematol. 2010. PMID: 20497178 Free article. Clinical Trial.
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E. Nilsson-Ehle H, et al. Among authors: nilsson l. Eur J Haematol. 2011 Sep;87(3):244-52. doi: 10.1111/j.1600-0609.2011.01654.x. Epub 2011 Jul 26. Eur J Haematol. 2011. PMID: 21623919 Clinical Trial.
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E. Möllgård L, et al. Among authors: nilsson l. Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669. Haematologica. 2011. PMID: 21719884 Free PMC article. Clinical Trial.
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Öster Fernström A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E. Rasmussen B, et al. Among authors: nilsson l. Leukemia. 2022 May;36(5):1436-1439. doi: 10.1038/s41375-022-01537-w. Epub 2022 Mar 11. Leukemia. 2022. PMID: 35277655 Free PMC article. Clinical Trial. No abstract available.
2,140 results